| Date | Form | Description | Docs | XBRL | Pages |
| 01/29/97 | 10-K405 | Annual report [Sections 13 and 15(d), S-K Item 405] |
|
35 | |
| 11/27/96 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans |
|
11 | |
| 09/13/96 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
13 | |
| 06/24/96 | DEF 14A | Definitive proxy statements |
|
14 | |
| 06/19/96 | 10-C |
|
2 | ||
| 06/18/96 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
1 | |
| 06/18/96 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
2 | |
| 06/14/96 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
4 | |
| 06/13/96 | 10-Q | Quarterly report pursuant to sections 13 or 15(d) |
|
14 | |
| 04/24/96 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
4 |
Latest News & Events
Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
Read More...Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th
Read More...Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial
Read More...